Verastem Oncology (VSTM) Q3 2026 earnings review
Verastem's pancreatic cancer pill impresses, but its drug sales slip
Verastem's experimental pancreatic cancer pill produced strong trial results, but sales of its approved ovarian cancer drug slipped. The drug developer said the pill shrank tumors in 41% of patients whose earlier pancreatic treatment had failed. Ovarian drug sales fell 4% from last quarter, and chief executive Dan Paterson now expects "a more gradual sales ramp". In October, Verastem sold $250 million of new shares.
| Sales of its ovarian cancer drug | $24.0M $25.1M last quarter |
|---|---|
| Research spending | $68.8M +66% from last quarter |
| Pancreatic patients whose tumors shrank on VS-7375 | 41% 50% when used as a second treatment |
| Cash plan | Extended into the first half of 2028, from the second half of 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because the pill passed its first real test, and Verastem now has money for final-stage trials. Its cash should last into the first half of 2028. The bad news: drug sales cover the sales team but not the drug's own trials, and fewer new patients started treatment.
The question now is whether the pill's results hold in bigger trials. If response rates stay close to the early ones, Verastem can seek a fast approval; if they drop to rivals' levels, the pill becomes one option among several. Mid-stage pancreatic data in the second quarter of 2027 will tell.
🐂 Bull Case
Pancreatic Pill Shrank Tumors in 41% of Patients
VS-7375 is Verastem's experimental pill against KRAS G12D, a faulty gene behind many pancreatic, lung and bowel cancers. Chief executive Dan Paterson said its first US data "established a new monotherapy efficacy benchmark in metastatic pancreatic cancer". Before October, the main worry was that the pill would not stand out from rival drugs.
In October, Verastem reported results from TARGET-D 101, its early-stage trial. It counted only responses that a second scan confirmed, as regulators do.
- Pancreatic cancer after earlier treatment: 41% of 22 patients responded
- Pancreatic cancer as a second treatment: 50% of 8 patients
- Lung cancer after earlier treatment: 43% of 23 patients
These numbers matter because daraxonrasib, an approved drug from Revolution Medicines, shrank tumors in 24% of such second-treatment patients with this gene, according to Verastem's slides. But the groups are small, and Verastem itself warns that comparisons across trials may not hold. Its bowel cancer result rests on just six patients.
What to watch: first results from TARGET-D 201, the larger mid-stage pancreatic trial, due in the second quarter of 2027. A response rate near today's level would support Verastem's case for a fast approval.
Share Sale Funds Verastem Into 2028
In its June filing, Verastem reported "substantial doubt about its ability to continue as a going concern", because it expected years of losses. In October, the drug developer sold about 31 million new shares for $250 million before fees.
Its new quarterly filing says the offering "alleviated the substantial doubt". Finance chief Dan Calkins said cash of $422.8 million, counting the October money, should fund operations into the first half of 2028. That plan covers the start of three final-stage trials. In August, Verastem had said its money would last into the second half of 2027.
Existing shareholders paid for this. The sale lifts the share count by about a third, and it ends the effort to borrow against future drug sales instead of selling stock. By our math, the quarter used about $57 million of cash before a one-off $15 million milestone payment.
What to watch: cash use in the fourth quarter, reported in early 2027. At this quarter's pace the money covers about seven quarters by our math, so any further rise in costs would bring the end date forward.
🐻 Bear Case
Ovarian Drug Sales Fell 4% From Last Quarter
Verastem's only approved product is AVMAPKI FAKZYNJA CO-PACK, a two-drug pack for low-grade serous ovarian cancer, a rare form of the disease. Its sales rose by about a third in the second quarter, and Verastem called that a rebound after a weak start to the year.
In the third quarter, sales slipped to $24.0 million from $25.1 million. Refills grew, Verastem said, but it also reported "fewer new patient starts due to seasonal headwinds, the implementation of recent commercial team changes, and evolving patterns of off-label use".
Unlike the summer slowdown, that last reason may persist. Some doctors had prescribed the pack for pancreatic cancer, a use regulators have not approved. Chief commercial officer Dan Lyons said a newly approved pancreatic cancer drug and new trials mean "we anticipate an impact on the business as the treatment patterns evolve". So part of the sales base may shrink just when Verastem needs the drug's cash.
What to watch: fourth-quarter sales, due in early 2027, and whether Verastem publishes new patient numbers. A second quarter without growth would show that refills alone cannot keep sales rising.
The Drug Covers Its Sales Team, Not Its Trials
In August, Verastem said the ovarian drug pack would pay for its sales operations and for trials of the drug pair by late 2026. Finance chief Dan Calkins now calls the franchise "self-sustaining from a commercial operations standpoint".
- Profit after production costs: $20.3 million
- Sales and medical-support costs: 69.5% of sales, up from 65.3% last quarter
- Trials and manufacturing for the drug pair: $11.1 million
- Shortfall against the August test: about $7.5 million, by our math
Calkins's test is narrower than the one Verastem set, because it leaves out the drug's own trials. Those include the confirmatory study that regulators require to keep the approval. A 4.5% royalty to lender Oberland also comes off every sale now.
What to watch: the cost split in the annual report, due in early 2027. If sales stay near this quarter's level, the drug will miss the August test for the year.
Research Spending Rose 66% in One Quarter
Verastem now runs four trials of VS-7375, its experimental pill for pancreatic, lung and bowel cancers, and plans three final-stage ones. Research spending reached $68.8 million, against $41.3 million in the second quarter. Finance chief Dan Calkins described these costs as "increasing as expected".
The bill will keep growing. Verastem's filing tied the jump to more patients, start-up work on three mid-stage trials and early work on the first final-stage trial. By our math, the pill took about 68% of research spending. Its manufacturing bill alone rose almost fivefold from a year ago, as the drug developer builds supply for bigger trials.
What to watch: fourth-quarter research spending, reported in early 2027. Another rise of this size would shorten the time the October money lasts.
Risks this quarter didn't answer
Four standing concerns got no new numbers this quarter. Each one still waits for a specific disclosure, listed below with the reading that would move it.
- New patients, refills and time on treatment: Verastem again gave no counts, not even a prescriber total; a published figure would show whether patients stay on the drug.
- Debt tied to drug sales: Oberland's last $25 million tranche requires quarterly sales about two-thirds above this level before May 2027, by our math.
- Reliance on two distributors: they bought $20.2 million of the $24.0 million sold; the annual report will show whether that share falls.
- Confirmatory trial: RAMP 301 reports in mid-2027 and decides whether the ovarian drug keeps its early approval.
👓 Other Themes
FDA Lets Response Rate Count in Pancreatic Trial
Verastem said the FDA agreed that TARGET-D 301, its final-stage pancreatic trial, can use response rate (ORR) as one of two main goals. Survival becomes a secondary goal because chemotherapy patients may switch to the pill. President of development Michael Kauffman said Verastem lacks "explicit agreement that FDA will accept an accelerated approval based on ORR from this study".
Blister Pack Could Replace Four Capsules With One
The FDA accepted Verastem's application for a new version of the ovarian drug pack and put it on a faster review track, with a decision due by February 7, 2027. A single tablet would replace four capsules per dose. Chief commercial officer Dan Lyons said the pack, by "eliminating the current refrigeration requirement", should help patients stay on treatment.
Michael Bailey Becomes Chief Executive in January
Dan Paterson retires as chief executive at the end of 2026, after 15 years at Verastem, and stays on the board. Michael Bailey, a Verastem director who previously ran AVEO Pharmaceuticals through its sale to LG Chem, takes over on January 1, 2027. Bailey will lead the start of the final-stage trials.
💲 Other KPIs
The share of each sales dollar left after production costs held steady. It has stayed near 85% for five quarters, in line with the run rate finance chief Dan Calkins pointed to in August. The filing warns that production costs will climb as stock made before approval runs out.
Money owed by distributors barely moved from $10.2 million in March. It equals about 38 days of drug sales, against about 55 days a year ago, so distributors pay on time and do not appear to be building stock.
The underlying loss widened by 86% from a year ago, to $0.72 per share. The reported loss looks smaller only because last year carried a $55.9 million charge on warrants, rights to buy shares at a set price. Research costs explain most of the gap.
🔮 Guidance
Raised. Verastem now expects its money, including the October share sale and drug sales, to last into the first half of 2028. That covers starting three final-stage trials. The new shares, not higher sales, explain the extra time.
Unchanged. Finance chief Dan Calkins expects overhead and selling costs to stay flat in the fourth quarter. The company kept that promise this quarter, though the base it holds to rose by about $5 million in the spring.
Unchanged. Verastem still plans to open its first final-stage trial of VS-7375, in newly diagnosed pancreatic cancer, by December. President of development Michael Kauffman said Verastem is signing contracts with trial sites.
Unchanged. Verastem plans to review the designs of TARGET-D 302 in lung cancer and TARGET-D 303 in bowel cancer with the FDA before the year ends.
Unchanged. The plan still has the first patients entering both trials in the first half of 2027, after the FDA meetings.
Unchanged from October. The August plan had all three trials full by the end of 2026, so the lung trial now runs about one quarter later.
Delayed. Verastem moved this readout from year-end 2026 to the first quarter of 2027, to follow patients for longer. The current result rests on six patients.
Delayed. The data now arrive in early second quarter 2027 rather than the first quarter, timed for a medical meeting.
Unchanged. Pancreatic results come first, in the second quarter of 2027, and lung and bowel results follow in the second half.
New. Verastem will report the pill combined with cetuximab, an antibody drug, in pancreatic cancer early in 2027 at a medical meeting.
Unchanged. The trial that must confirm the ovarian drug's early approval still reports its main result in the middle of 2027.
New. The FDA set this date after accepting the application in October with a faster review.
❓ Key Questions
How many new patients started the ovarian drug?
Verastem blamed fewer new starts for the sales dip but again gave no count of starts, refills, prescribers or time on treatment. Without them, readers cannot tell whether refills can keep sales rising.
How much of the drug's sales came from pancreatic cancer?
Chief commercial officer Dan Lyons expects off-label pancreatic use to fade as new treatments arrive. The size of that use tells readers how much of the current sales base is at risk.
When will the drug pay for its own trials?
Finance chief Dan Calkins now calls the franchise self-sustaining on sales operations only. By our math, it fell about $7.5 million short once the drug pair's trials count.
Will Verastem reach the sales level for Oberland's last tranche?
The final $25 million needs a $40 million sales quarter before May 15, 2027. Sales would have to rise about two-thirds from this quarter, by our math.
How high will research spending go next year?
Research costs rose two-thirds in one quarter, and three final-stage trials start by mid-2027. A spending range for 2027 would show how firm the cash plan into 2028 is.